KB-1731

RMP114-mIgG2a-PGLALA

56506

Home » Antibodies » RMP114-mIgG2a-PGLALA

Background of RMP114-mIgG2a-PGLALA

The RMP1-14 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. However, RMP1-14 mAb is produced in rats and is therefore immunogenic in mice, and can promote antibody-dependent cytotoxicity. To overcome this issue, RMP114-mIgG2a was generated by recombinant DNA technology.

Specifications

Catalog Number	KB-1731
Antibody Name	RMP114-mIgG2a-PGLALA
Isotype	Mouse IgG2a,kappa
Target	Mouse PD1
Species Reactivity	Mouse
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
Yamazaki T. et al.,2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.
Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157.
Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 5(2):e1075114.